Nordic Biomarker Acquires Nordic Haemostasis and Expands Control Portfolio

We are proud and happy to announce that we are now able to offer you controls not only for laboratory environment, but also for point-of-care (POC) use.

Nordic Biomarker has acquired Nordic Haemostasis, a company based in Linköping, Sweden, that focuses on POC controls for coagulation diagnostics. Their main clients are external quality assessment organisations (EQA) and POC instrument providers.
“We are excited to enter a new segment and get to serve POC customers and EQA organisations. Nordic Haemostasis’ liquid POC controls are yet another piece that will complete our coagulation portfolio nicely”, says Rikard Rodén, CEO at Nordic Biomarker.

Professor Tomas Lindahl, one of the founders of Nordic Haemostasis, is happy about the acquisition.
“We have been wanting to pass the torch for some time, and as Nordic Biomarker takes over, we know that both our products and our customers will come into good hands.”

The products that will now be incorporated into Nordic Biomarker’s portfolio are:

• Liquid plasma control for D-dimer analysis
• Liquid plasma control for PT-INR analysis
• Lyophilised whole blood control for PT-INR analysis
• Lyophilised whole blood control for ACT analysis

In addition to the products themselves, Nordic Biomarker gets ownership of and access to development projects and liquid control technology that will lead to exciting product launches in the years to come.

During 2023, Nordic Haemostasis will continue to operate as an independent wholly owned subsidiary. If you are interested in evaluating or buying these new products, please contact Nordic Haemostasis at info@nordic-haemostasis.com or find out more about the new products on Nordic Haemostasis’ website. As always, you are also welcome to ask your sales contact.